Kedrion Biopharma
Chris Shields currently serves as Senior Manager of Business Intelligence and Sales Operations at Kedrion Biopharma, a position held since November 2023. Prior to this role, Chris was with Merz Therapeutics from August 2021 to November 2023, where responsibilities included Senior Manager of Commercial Analytics and Sales Operations, as well as Commercial Analytics Business Partner. Experience at bioMérieux from December 2016 to August 2021 included the role of Senior Director of Finance for Industry Americas. Earlier positions include Business Planning Analyst at Northrop Grumman Corporation, Functional Analyst at CACI International Inc, and various roles at Digitek Computer Products, culminating as Senior Purchasing Agent. Chris holds an AP Diploma from Oakton High School, earned in 2006.
This person is not in any teams
This person is not in any offices
Kedrion Biopharma
19 followers
Kedrion Biopharma is a biopharmaceutical company that collects and fractionates blood plasma to produce and distribute worldwide plasma-derived therapies for use in treating and preventing rare and serious diseases and conditions. In 2022, Kedrion joined forces with BPL (Bio Products Laboratory). Based in the United Kingdom, BPL has over 60 years of experience in the supply of high-quality plasma-derived medicines to treat rare diseases. Kedrion distributes its products in over 100 countries around the world. We have plants in Italy, Hungary, UK and North America, and plasma collection centers in the US and in the Czech Republic. With these figures we are the world’s 5th top player in the field of plasma-derived products. Our goal is to build a diverse and professional workforce, providing job opportunities for talented external candidates as well as internal employees who aim to grow with us. Because our work includes so many interests and skills – from Research to Sales; Plasma Collection to Production – there are abundant possibilities for learning and growth. Kedrion builds bridges: from donors to patients, from plasma to therapies, from challenge to hope.